基础医学与临床 ›› 2024, Vol. 44 ›› Issue (9): 1256-1262.doi: 10.16352/j.issn.1001-6325.2024.09.1256

• 研究论文 • 上一篇    下一篇

吴茱萸碱对特应性皮炎模型大鼠的治疗作用

蒋苏*, 吕新翔, 崔艳红, 吕李婷, 李东霞   

  1. 内蒙古医科大学附属医院 皮肤性病科,内蒙古 呼和浩特 010050
  • 收稿日期:2024-02-26 修回日期:2024-05-09 出版日期:2024-09-05 发布日期:2024-08-30
  • 通讯作者: *jush2462280@163.com
  • 基金资助:
    内蒙古医科大学青年创新基金(YKD2017QNCX050)

Therapeutic effect of evodiamine on atopic dermatitis in rat models

JIANG Su*, LYU Xinxiang, CUI Yanhong, LYU Liting, LI Dongxia   

  1. Department of Dermatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
  • Received:2024-02-26 Revised:2024-05-09 Online:2024-09-05 Published:2024-08-30
  • Contact: *jush2462280@163.com

摘要: 目的 探讨吴茱萸碱(Evo)调节环磷酸腺苷(cAMP)/蛋白激酶A(PKA)/cAMP反应元件结合蛋白(CREB)信号通路对特应性皮炎(AD)模型大鼠的治疗作用。方法 通过多次2,4-二硝基氯苯(DNCB)涂抹建立AD大鼠模型,随机分为AD组、Evo低剂量(Evo-L,5 mg/kg)组、Evo高剂量(Evo-H,10 mg/kg)组、Evo-H+H-89(5 mg/kg)组、地塞米松(0.1 mg/kg)组,并以正常大鼠为对照组,随后对各组大鼠皮损程度进行评分;腹部取血,检测血清中白细胞介素(IL)-4、cAMP、肿瘤坏死因子(TNF)-α水平;收集皮损组织,检测皮损组织病理学变化、肥大细胞数量、组织中PKA/CREB相关蛋白表达以及IL-4、TNF-α mRNA表达。结果 与对照组相比,AD组大鼠血清中cAMP水平、皮损组织中p-PKA/PKA、p-CREB/CREB表达降低,皮损程度评分、IL-4、TNF-α水平、表皮厚度、肥大细胞数、皮损组织中IL-4、TNF-α mRNA表达增加(P<0.05);与AD组相比,Evo-L组、Evo-H组、地塞米松组大鼠血清中cAMP水平、皮损组织中p-PKA/PKA、p-CREB/CREB表达增加,皮损程度评分、IL-4、TNF-α水平、表皮厚度、肥大细胞数、皮损组织中IL-4、TNF-α mRNA表达降低(P<0.05);与Evo-H组相比,与Evo-H+H-89组大鼠血清中cAMP水平、皮损组织中p-PKA/PKA、p-CREB/CREB表达降低,皮损程度评分、IL-4、TNF-α水平、表皮厚度、肥大细胞数、皮损组织中IL-4、TNF-α mRNA表达增加(P<0.05)。结论 Evo调节cAMP/PKA/CREB信号通路抑制AD模型大鼠的炎性反应及病理损伤。

关键词: 吴茱萸碱, cAMP/PKA/CREB信号通路, 特应性皮炎, 炎性反应

Abstract: Objective To evaluate the therapeutic effect of evodiamine (Evo) on atopic dermatitis (AD) in rat models by regulating the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/cAMP response element binding protein (CREB) signaling pathway. Methods A rat model of AD was established by administration of multiple doses of 2,4-dinitrochlorobenzene (DNCB).The animals were randomly divided into AD group, Evo-low-dose (Evo-L, 5 mg/kg) group, Evo-high-dose (Evo-H, 10 mg/kg) group, Evo-H+H-89 (5 mg/kg) group and dexamethasone (0.1 mg/kg) group. Normal rats were used as the control group and then the degree of skin damage of rats in each group was scored. Abdominal blood was taken to detect the levels of interleukin-4 (IL-4), cAMP, and tumor necrosis factor-α(TNF-α) in serum; Skin lesion tissue was collected to detect pathological change, counting of mast cells, PKA/CREB related protein expression and expression of IL-4 and TNF-α mRNA in the tissue. Results Compared with control group, the level of cAMP in serum, the expression of p-PKA/PKA, and p-CREB/CREB in skin lesions of AD group were reduced, the severity score of skin lesions, level of IL-4 and TNF-α, epidermal thickness, number of mast cells and mRNA expression of IL-4 and TNF-α in skin lesion tissues were all significantly increased (P<0.05). Compared with AD group, the level of cAMP in serum, the expression of p-PKA/PKA, and p-CREB/CREB in skin lesions in Evo-L group, Evo-H group, and dexamethasone group were increased, the severity score of skin lesions, level of IL-4 and TNF-α, epidermal thickness, number of mast cells, and mRNA expression of IL-4 and TNF-α in skin lesion tissues all reduced (P<0.05). Compared with the Evo-H group, the level of cAMP in serum, the expression of p-PKA/PKA, and p-CREB/CREB in skin lesions in Evo-H+H-89 group was reduced and the severity score of skin lesion, level of IL-4 and TNF-α, epidermal thickness, number of mast cells, and mRNA expression of IL-4 and TNF-α in skin lesion tissues significantly increased(P<0.05). Conclusions Evo inhibits inflammatory response and pathological damage through regulation of cAMP/PKA/CREB signaling pathway in AD rat models.

Key words: evodiamine, cAMP/PKA/CREB signaling pathway, atopic dermatitis, inflammation

中图分类号: